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Pancreatic cancer is a devastating disease with a five-year survival rate of 5.6%.  Approximately 
5 – 10% of cancer diagnoses are due to a hereditary predisposition.  While some cancer 
syndromes have been shown to increase the risk for pancreatic cancer above the population risk 
of ~2%, a gene for familial pancreatic cancer has not been identified.  In either of these 
situations, surveillance for high-risk individuals has not been well established as compared to 
other more common cancers associated with hereditary cancer syndromes.  The goal of this study 
is to identify familial individuals’ top motivation for attending the high-risk pancreas clinic, and 
for those individuals who elect endoscopic ultrasound, assess if their feelings about their cancer 
risk and level of worry change after the procedure. 
For this study, a high-risk, unaffected population was recruited, along with a comparison 
group of individuals referred for endoscopic ultrasound due to a pancreatic abnormality.  Using 
the Health Belief Model as a framework, participants were asked to complete two validated 
questionnaires pertaining to their cancer risk perception and level of worry about pancreatic 
cancer.  The first questionnaire was completed before the endoscopic ultrasound, and the second 
questionnaire was sent home with the participant after the procedure for completion. 
Data analysis revealed both similarities and differences in the two cohorts.  Both 
populations showed similar trends in the benefits of the endoscopic ultrasound and the fear of the 
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procedure due to a potential negative outcome.  Family history and familial support 
demonstrated the largest difference in trend values between the case and comparison cohorts 
This study has public health importance because of the serious consequences of 
pancreatic cancer.  High-risk individuals are looking for surveillance options to improve the 
early detection of pancreatic cancer, and to date, there is not an established surveillance protocol.  
As more research is done, a better understanding of the psychosocial impact of surveillance in 
this population can be better understood. 
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1.0  INTRODUCTION 
Approximately 5 – 10% of pancreatic cancers are due to an inherited predisposition.  Individuals 
have an increased risk for developing pancreatic cancer based on the number of affected family 
members with pancreatic cancer and other cancers in the family medical history, as well as the 
presence of a known germline mutation.  Germline mutations are heritable changes in the DNA 
sequence that can be passed from generation to generation.  Current technologies, including MRI 
and endoscopic ultrasound, are used for surveillance of the pancreas in this high-risk, healthy 
patient population. 
Little is known about the effectiveness of surveillance for pancreatic cancer using 
endoscopic ultrasound.  It is unclear how well the procedure detects early stage pancreatic cancer 
in this high-risk population, when cancer may be more treatable.  As part of the informed consent 
process, the limitations of the testing should be explained to all patients having the procedure.  
Symptomatic patients and those with a pancreatic cancer diagnosis may not see the limitations of 
endoscopic ultrasound as a barrier for the test.  This may be due to the fact that endoscopic 
ultrasound is being used as a diagnostic test rather than as a surveillance tool.  
To explore the cancer risk perception in two populations, the Health Belief Model was 
used as a framework for this study.  These two populations were considered either high-risk 
cases or comparisons.  Cases are defined as those asymptomatic individuals with a family history 
of pancreatic cancer who undergo endoscopic ultrasound as a surveillance tool.  Comparisons are 
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categorized as those individuals who are symptomatic patients who are using endoscopic 
ultrasound as a diagnostic tool.  The aim of this study is to identify familial individuals’ top 
motivation for attending the high-risk pancreas clinic.  In addition, for those high-risk individuals 
who elect to have the endoscopic ultrasound, the study examined their perceptions of cancer risk 
and cancer worry before and after the endoscopic procedure. 
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2.0  BACKGROUND 
2.1 THE PANCREAS 
The pancreas is a vital organ located in the abdomen, behind the stomach.  It contains two 
different types of glands: exocrine and endocrine.  About 95% of the pancreas is made up of 
exocrine cells (American Cancer Society).  These cells create enzymes required for digestion.  
These enzymes flow through small ducts that eventually merge with the pancreatic duct. A small 
percentage (about 5%) of pancreatic cells are endocrine cells and are arranged in small clusters 
known as islets of Langerhans (American Cancer Society).  These cells are responsible for 
releasing important hormones like insulin and glucagon into the blood stream to control the 
amount of sugar present.  Diabetes can result from the inability of these cells to produce insulin.  
The pancreas also has an extensive duct system.  The main duct connects the pancreas to the 
common bile duct at the ampulla of Vater and transports the digestive enzymes into the 
duodenum.   
Exocrine and endocrine cells form completely different types of tumors.  Endocrine 
tumors are quite rare and are termed neuroendocrine tumors.  They are typically named for the 
hormone-making cell they start in (e.g. insulinomas, glucagonomas, gastrinomas).  Exocrine 
tumors are the most common type found in the pancreas.  Adenocarcinomas tend to start in the 
glands of the pancreas, while less common tumors arise from the pancreatic ducts.  The deep 
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location in the abdomen is not conducive to palpable tumors.  These tumors are the main focus of 
this study. 
2.2 GENERAL FACTS OF PANCREATIC CANCER 
Pancreatic cancer is the fourth most common cancer in both men and women in the United States 
(Lewis et al., 2009).  The incidence of pancreatic cancer in African Americans is higher than in 
Caucasians.  Pancreatic cancer is seen in 13.5 per 100,000 Caucasian males and 10.5 per 100,000 
Caucasian females (Klein, 2012).  In the African American population, the risk to males is 17.1 
per 100,000 and 14.8 per 100,000 in females.  According to the American Cancer Society, the 
lifetime risk to develop pancreatic cancer in the general population is approximately one in 71 or 
1.41%.  Approximately 80% of pancreatic cancers have already metastasized when diagnosed 
(Klein, 2012).  These diagnoses are usually made after the patient has become symptomatic due 
to the metastasis.  The most common presenting symptoms in metastatic patients are epigastric 
pain, weight loss, and obstructive jaundice (Brand et al., 2007).  Overall five-year survival rate is 
only 5.6% (Stoita et al., 2011).  Once a diagnosis has been made, the median survival rate is 
around six months (Stoita et al., 2011).   
2.2.1 Types of pancreatic cancer 
The most common type of pancreatic cancer is adenocarcinomas of the pancreas.  It accounts for 
greater than 90% of diagnoses (Brand et al., 2007).  As of now, there are three known precursor 
lesions to pancreatic cancer.  Intraductal papillary mucinous neoplasm (IPMN) is the most likely 
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precursor to turn malignant.  Approximately 70% of main duct IPMN and 25% of branch duct 
IPMN are found to be malignant (Stoita et al., 2011).  The second type of precursor lesion is 
known as the pancreatic intra-epithelial (PanIN).  This type of lesion is the most common type 
found.  The third type of precursor lesion is a mucinous cystic neoplasia (MCN).  PanINs and 
IPMNs are the most common lesions seen in patients with a strong family history of pancreatic 
cancer (Shi et al., 2009).  Larger lesions, including main duct IPMNs and MCNs, can be detected 
by CT and MRI.  Smaller pancreatic changes, like branch duct IPMNs and chronic pancreatitis, 
are best detected using an endoscopic ultrasound (Stoita et al., 2011).  
2.2.2 Risk Factors 
The most important risk factor for pancreatic cancer is age.  More than 80% of individuals 
diagnosed with pancreatic cancer are between the ages of 60 and 80 (Brand et al., 2007).  Almost 
all patients are over the age of 45, with the average age of diagnosis being 72 (American Cancer 
Society).  Risk factors for pancreatic cancer have been separated into three subgroups of relative 
risk.  Relative risk is defined as the ratio of the incidence of a disease among individuals with a 
given risk factor (e.g. a genetic mutation, lifestyle choice, environmental exposure) versus the 
incidence of a disease among individuals without a given risk factor (i.e. the general population).  
These groups are based on the degree to which they increase the risk for developing pancreatic 
cancer over that of the general population.  Those risk factors that increase the cancer risk by less 
than five-fold over the general population are placed in the “low” group.  Those risk factors that 
increase the cancer risk between five and ten-fold are in the “moderate” group.  The “high” 
group are those factors that increase the risk by greater than ten-fold. 
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2.2.2.1 Low (<5-fold) 
Those risk factors in the low category increase the risk for pancreatic cancer less than five-fold 
above the general population (Brand et al., 2007).  Individuals who are male, of African 
American decent, or of Ashkenazi Jewish descent have a two-fold increased risk to develop 
pancreatic cancer.  The most significant lifestyle risk factor is cigarette smoking.  Active 
smoking has been shown to carry a 1.77-fold increased risk for pancreatic cancer (Lynch et al., 
2008).  Former smokers have a 1.2-fold increased risk (Klein, 2012).  Fifteen years after 
smoking cessation, individuals have a similar risk to those who have never smoked (Lynch et al., 
2008).  Diabetes mellitus has also been shown to increase the risk for pancreatic cancer.  The 
overall risk is a 1.94-fold increase over the general population (Ben et al., 2010).  This risk 
seems to be the highest within the first year of diabetes mellitus diagnosis.   
Increased body mass also seems to be a risk factor for pancreatic cancer.  Normal body 
mass index (BMI) is between 18.9 and 24.9.  Individuals with a BMI greater than 35 have a 1.19-
fold increased risk to develop pancreatic cancer (Berrington de Gonzalez et al., 2003).  Excessive 
alcohol consumption is another lifestyle risk factor.  Consumption of six or more drinks per day 
has a 1.46-fold increased risk for pancreatic cancer (Klein, 2012).  Other risk factors in this 
group include an Helicobacter pylori infection, a history of any cancer in a first-degree relative, 
hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, individuals with a 
BRCA1 mutation, and a history of pancreatic cancer in one first-degree relative (Brand et al., 
2007).  First-degree relatives are those family members that share 50% of the genetic material 
with the proband.  This includes parents, children, and siblings. 
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2.2.2.2 Moderate (5 – 10-fold) 
An example of a moderate risk factor for pancreatic cancer is the Mendelian condition cystic 
fibrosis (CF).  CF is an autosomal recessive condition characterized by abnormal transport of 
sodium and chloride across the epithelial layer.  This leads to thick, viscous secretions primarily 
found in the lungs, pancreas, and GI tract.  One report indicates a 2.6-fold increased risk for 
pancreatic cancer, while another report shows a 32-fold increased risk, with a confidence interval 
from 4.8 to 205 (Brand et al., 2007).  Depending on the mutation in the CFTR gene, the amount 
of pancreatic and GI involvement may differ.   
Chronic pancreatitis also falls into the moderate risk category.  Chronic pancreatitis is 
associated with repeated inflammation of the pancreas.  This long-standing inflammation affects 
the structure and function of the pancreas.  There is also conflicting data about the true risk 
associated with this condition.  One report shows between a 16.5 and 19-fold increased risk for 
pancreatic cancer, while another showed only a two-fold increase (Brand et al., 2007).  Because 
of the variability of both of these conditions, they have been placed in the moderate group 
(Brand et al., 2007).  Other factors in this group include a family history of pancreatic cancer in 
two first-degree relatives and BRCA2 mutation carriers. 
2.2.2.3 High (>10-fold) 
A majority of risk factors in the high category are those with a hereditary predisposition to 
pancreatic cancer.  These include FAMMM kindreds with an identified p16 mutation and at least 
one case of pancreatic cancer in a first- or second-degree relative, Peutz-Jeghers syndrome, 
hereditary pancreatitis, and a family history of three or more first, second, or third-degree 
relatives with pancreatic cancer (Brand et al., 2007).  For the purposes of this paper, kindred is 
defined as a group of related individuals.  New evidence supports placing BRCA1/2 families with 
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at least one case of pancreatic cancer in first or second-degree relatives into this high-risk group 
(Brand et al., 2007). 
2.2.2.4 Gene-Environment Interactions 
Studies have suggested that there is a direct link between genetic and environmental interactions 
that carry an increased risk for pancreatic cancer.  For this section, environmental risk factors 
also include those that are considered lifestyle risk factors.  It has been shown that there may be 
an additive risk when combining genetic and environmental risk factors in a single individual.  
One example of this is the combination of hereditary pancreatitis and cigarette smoking.  
Hereditary pancreatitis alone holds a risk of 53-fold greater than the general population 
(Lowenfels et al., 1997).   But when an individual is also a smoker, his risk is elevated to 154-
fold above the general population (Lowenfels et al., 2001).  It is thought that the combination of 
progressive glandular damage from the pancreatitis and the chemicals from cigarette usage leads 
to this significantly increased risk for pancreatic cancer (Lowenfels et al., 2001).  Additionally, 
there also seems to be a correlation with the onset of pancreatic cancer in these individuals.  
Non-smokers with hereditary pancreatitis seem to have an average age of onset around 70 years 
of age, while those individuals who are smokers see an age of onset around 50 (Matsubayashi, 
2011).  It is important to educate individuals at increased risk for pancreatic cancer due to a 
hereditary predisposition about the increased risk associated with environmental factors.  
Smoking, obesity, and diabetes mellitus are all environmental factors that are shown to carry an 
increased risk due to a gene-environment interaction. 
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2.3 HEREDITARY CANCER SYNDROMES 
Cancer is a disease known throughout the world.  It is estimated that one in three individuals will 
develop cancer at some point in his/her lifetime (American Cancer Society).  It is estimated that 
approximately 5 – 10% of all diagnoses result from an inherited gene mutation.  There are 
specific features that suggest an inherited predisposition to cancer: multiple cancer diagnoses in a 
family with some under the age of 50, multiple generations with a related cancer diagnosis, 
individuals with multiple primary tumors, unusual or rare tumors, and/or families from a specific 
ethnic background known to have an increased carrier frequency (Lindor & Greene, 1998).  
Several hereditary cancer syndromes are associated with an increased risk for pancreatic cancer.  
Much like the overall cancer statistics, it is believed that approximately 5 – 10% of all pancreatic 
cancer diagnosed result from an inherited gene mutation (Matsubayashi, 2011).  The increased 
risk for pancreatic cancer spans anywhere between 5 – 40%, depending on the specific syndrome 
and/or the number of family members affected (Maheu et al., 2010). 
2.3.1 Peutz-Jeghers Syndrome (PJS) 
Peutz-Jeghers syndrome is an autosomal dominant cancer syndrome associated with multiple 
gastrointestinal hamartomatous polyps and pigmented spots on the lips and buccal mucosa.  It is 
caused by mutations in the STK11 gene, a serine threonine kinase gene that acts as a tumor 
suppressor.  The prevalence is approximately one in 8,300 – 280,000 (Matsubayashi, 2011).  A 
clinical diagnosis can be made in an individual with one of the following features: two or more 
histologically confirmed PJS polyps, any number of PJS polyps detected in one individual who 
has a family history of PJS in a close relative, characteristic mucocutaneous pigmentation in an 
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individual who has a family history of PJS in a close relative, or any number of PJS polyps in an 
individual who has characteristic mucocutaneous pigmentation (NCCN).  Individuals diagnosed 
with PJS have an overall lifetime cancer risk of 70% (van Lier et al., 2010).  The overall cancer 
risk is also associated with 60% of deaths in the PJS population (Boardman et al., 1998).  Studies 
have shown that the pancreatic cancer risk is 132-fold above the general population in these 
families, with a lifetime risk of 11 – 32% (van Lier et al., 2010).  These individuals also have an 
age of onset around 40, earlier than other hereditary syndromes (Matsubayashi, 2011).   
2.3.2 Hereditary Pancreatitis 
Hereditary pancreatitis is an inherited form of chronic pancreatitis that is characterized by 
repeated attacks of acute pancreatitis, or inflammation of the pancreas.  These repeated attacks 
start early in life and lead to long-term exocrine and endocrine damage.  The natural history and 
prevalence of hereditary pancreatitis has not been well documented (Rebours et al., 2009).  A 
majority of these families have mutations in the cationic trypsinogen gene PRSS1, which results 
in the autosomal dominant form.  Mutations in the serine protease inhibitor gene, SPINK1, cause 
the autosomal recessive form.  Both types of mutations lead to early activation of the pancreatic 
enzymes that begin to digest the organ rather than waiting to activate in the duodenum.  
Regardless of the gene mutation, individuals have a 53-fold increased risk to develop pancreatic 
cancer (Lowenfels et al., 1997).   This condition also carries a lifetime risk for pancreatic cancer 
between 30 and 40% by age 70 (Ulrich et al., 2001), with this risk even higher among smokers.  
This diagnosis can occur 20 years earlier than in patients who do not smoke (Klapman et al., 
2008). 
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2.3.3 Familial Atypical Multiple Mole Melanoma (FAMMM) 
Familial Atypical Multiple Mole Melanoma is an autosomal dominant cancer syndrome 
characterized by multiple dysplastic nevi and melanoma.  It is caused by mutations in 
p16/CDKN2A, a tumor suppressor gene.  It is estimated that 5 – 7% of individuals with 
melanoma are from genetically high-risk families, though exact carrier frequencies are not 
known (Greene, 1997).  A clinical diagnosis can be made in a family with one or more first- or 
second-degree relatives with malignant melanoma or an individual with a total body nevi count 
of greater than 50 including some of which are clinically atypical (NCCN).  The two most 
common malignancies in FAMMM kindreds are melanoma and pancreatic cancer.  Other 
associated cancers include lung, breast, and sarcoma.  Studies have shown that the risk for 
pancreatic cancer in FAMMM kindreds is a 38-fold increase (Matsubayashi, 2011).  In familial 
melanoma families without a p16 mutation, the risk is estimated to be between a 13 and 22-fold 
increase (Lynch et al., 2008). 
2.3.4 Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC or Lynch 
Syndrome) 
Lynch syndrome is an autosomal dominant cancer syndrome associated with right-sided colon 
cancers and other abdominal malignancies.  It is caused by mutations in the mismatch repair 
pathway.  Lynch syndrome may account for 6 – 10% of all colon cancer diagnoses (Vasen et al., 
1996).  A clinical diagnosis can be made, in some cases, by the Amsterdam II criteria.  This 
includes three individuals with a Lynch syndrome-related cancer, with one relative being a first-
degree relative of the other two; two successive generations are affected; and one diagnosis must 
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occur under the age of 50 (NCCN).  Of note, Lynch syndrome-related cancers include 
endometrial, ovarian, small bowel, stomach, bile duct, and urinary tract.  Individuals from Lynch 
syndrome kindreds have an 8.6-fold increased risk for pancreatic cancer and a lifetime risk of 
3.86% (Kastrinos et al., 2009).  Interestingly, Lynch syndrome families with microsatellite 
instability are more prone to be diagnosed with medullary pancreatic cancer.  It is also believed 
that the prognosis is better in individuals with microsatellite unstable pancreatic cancers 
(Matsubayashi, 2011).   
2.3.5 Hereditary Breast and Ovarian Cancer Syndrome (HBOC) 
Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer syndrome 
primarily associated with an increased risk for breast and ovarian cancer, with additional cancer 
risks as well.  It is caused by mutations in the tumor suppressor genes BRCA1 and BRCA2.  
Carrier frequency in the general population is believed to be one in 500, although Founder 
populations (i.e. individuals of Easter European [Ashkenazi] Jewish ethnicity) may have a carrier 
frequency as high as one in 40 (Struewing et al., 1997).   Clinical characteristics of HBOC 
include: the presence of two or more breast and ovarian cancer diagnoses; early age of onset 
(defined as before age 50); generation-to-generation transmission; individuals with multiple 
primary tumors (e.g. bilateral breast cancer, breast and ovarian cancer); unusual tumors (e.g. 
ovarian cancer, pancreatic cancer); and Ashkenazi Jewish ethnic background (NCCN).  Studies 
have shown a 3.5-fold increased risk for pancreatic cancer in individuals with a BRCA2 mutation 
(The Breast Cancer Linkage Consortium, 1999).  With this association, the presence of 
pancreatic cancer in an “HBOC-looking” family is a good predictor of a BRCA2 mutation 
(Phelan et al., 1996).  It is believed that BRCA2 mutations are the most common gene 
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responsible for familial aggregations of pancreatic cancer (Matsubayashi, 2011).  There are 
conflicting reports about the risk for individuals with a BRCA1 mutation. Some studies have 
shown a 2.26-fold increased risk for pancreatic cancer, while others have shown no significant 
increased risk when compared to the general population (Thompson et al., 2002; Ferrone et al., 
2009).   
2.3.6 Familial Adenomatous Polyposis Syndrome (FAP) 
Familial adenomatous polyposis syndrome is an autosomal dominant cancer syndrome 
associated with a lifetime risk for colon cancer reaching 100%.  It is caused by mutations in the 
tumor suppressor gene APC, with 25% to 33% of cases being de novo.   The incidence of FAP is 
thought to be one in 6,000 – 13,000 (Rhodes et al., 1992).  A clinical diagnosis can be made in 
an individual with greater than 100 adenomas in the colon or an individual with fewer than 100 
adenomas and a family history of FAP (NCCN).  While the true risk associated with FAP is for 
colon and extra-colonic cancers, these individuals are also at a slightly increased risk for 
pancreatic cancer.  APC mutations are associated with a relative risk of 4.5 for pancreatic cancer 
(Giardiello et al., 1993).  However, it is thought that invasive duodenal cancer, a tumor strongly 
associated with FAP, may be mistaken as pancreatic cancer (Larghi et al., 2009).  Because of 
this, it may be an overestimation of the pancreatic cancer risk.  Aside from the adenocarcinoma 
of the pancreas, individuals are also at risk for pancreatoblastoma due to bi-allelic inactivation of 
APC (Matsubayashi, 2011).   
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2.3.7 Familial Pancreatic Cancer Syndrome (FPC) 
Familial pancreatic cancer syndrome is presumed to be an autosomal dominant cancer syndrome 
associated with a predisposition for developing pancreatic cancer.  Unlike the other hereditary 
cancer syndromes, the genetic basis of FPC has not been identified.  This syndrome is defined as 
a family with at least two first-degree relatives with pancreatic cancer (Stoita et al., 2011).  
Additionally, this diagnosis should be made only when all other cancer syndromes have been 
evaluated and excluded (Lindor & Greene, 1998).  Cancer risks in families with FPC have been 
identified based on the number of affected family members.  For individuals with two affected 
first-degree relatives, the relative risk for pancreatic cancer is 6.4%, with a lifetime risk of eight 
to twelve percent (Klein et al., 2004).  Individuals who have three affected first-degree relatives 
have a relative risk for pancreatic cancer of 32% and a lifetime risk of 16 – 32% (Tersmette et 
al., 2001).   
When evaluating a family for one of the established hereditary cancer syndromes, age of 
onset for pancreatic cancer is not typically taken into account because of its rarity.  However, age 
of onset is important when a family is being considered for a FPC diagnosis.  The risk for 
pancreatic cancer is higher in FPC kindreds when age of onset is younger than the average seen 
in other hereditary cancer syndromes (Stoita et al., 2011).  This is likely due to the fact that 
anticipation has been seen in FPC kindreds.  Anticipation is where the symptoms of a genetic 
disorder become apparent at an earlier age as it is passed on to the next generation.  In many 
cases, there is also an increase in the severity of the disease.  In 2006, McFaul et al. observed an 
age of onset difference of six years between generations.  It is important to note that anticipation 
is family specific.  The progress of individuals in one family towards an earlier onset should not 
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be relevant to the progression in another family, unless there is a common ancestor (McFaul et 
al., 2006). 
2.4 SURVEILLANCE FOR PANCREATIC CANCER 
At this time, no established guidelines exist for screening or surveillance for pancreatic cancer to 
assist health care professionals (Brand, 2011).  Routine screening for pancreatic cancer is not 
recommended for the general population.  However, a select subset of individuals may warrant 
further surveillance (Lewis et al., 2009).  It is important to note the difference between cancer 
screening and cancer surveillance.  Screening techniques are available to the general population 
as a means to detect early stage cancer.  There are a few cancers with a technique that has been 
proven to be effective in the general population.  These include mammography for breast cancer, 
colonoscopy for colon cancer, pap smears for cervical cancer, and the prostate-specific antigen 
(PSA) blood test for prostate cancer (American Cancer Society).  Surveillance techniques are 
those that are only made available to particular high-risk populations (American Cancer Society). 
The overall goal of surveillance is to detect precursor lesions or early pancreatic cancer 
when it may be at its most treatable stage (Stoita et al., 2011).  Premalignant lesions and small 
pancreatic cancers tend to be asymptomatic.  It is believed that stage I tumors less than two 
centimeters have a much better survival rate (58% at five years) when compared with stage IIb 
(17% at five years) (Stoita et al., 2011). 
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2.4.1 High-Risk Populations 
Who should be included in surveillance for pancreatic cancer has been widely debated.  For other 
common types of cancer, like breast and colon, surveillance algorithms have been created to 
capture appropriate populations (NCCN).  These same algorithms have not been extensively 
studied for the pancreatic cancer patient population due to the relatively small numbers (Larghi 
et al., 2009).  In 2003, experts gathered at the Fourth International Symposium of Inherited 
Diseases of the Pancreas.  With the lack of evidence for a solid algorithm, these experts created 
the consensus practice recommendations for pancreatic cancer surveillance (Brand et al., 2007).   
Surveillance is considered appropriate for individuals who have a greater than 10-fold 
increased risk for pancreatic cancer (Brand et al., 2007).  This group includes FAMMM, 
hereditary pancreatitis, PJS, and three or more first-, second-, or third-degree relatives with 
pancreatic cancer.  In families with a BRCA1 or BRCA2 mutation, surveillance may be 
considered when there is a first- or second-degree relative with pancreatic cancer (Brand et al., 
2007).  Other individuals may be considered for surveillance if they do not meet the criteria 
above, but may have compounding environmental risk factors that have increased their 
pancreatic cancer risk (Lewis et al., 2009).  There remains a question for individuals who fall 
into the 5 – 10-fold increased risk category.  It is suggested that until an algorithm of cost-
effectiveness vs. benefits to the individual is created for pancreatic cancer surveillance, 
surveillance may be used until further studies can establish a risk threshold (Larghi et al., 2009). 
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2.4.2 Surveillance Options: Benefits and Limitations 
Experts have not only debated who should have surveillance, but also the type of surveillance to 
offer and when to start surveillance.  Several surveillance options are available, and a variety of 
protocols have been proposed, but experts have not been able to reach a consensus on which 
protocol should be used as the standard of care for high-risk populations.  Endoscopic ultrasound 
(EUS) remains the best first-line imaging technique for pancreatic cancer (Lewis et al., 2009).  
The body and tail of the pancreas lie directly posterior to the stomach.  This position lends itself 
to a highly detailed endosonographic evaluation and the ability to biopsy any portion of the 
pancreas (Folkers et al., 2011).  An important point to make with high-risk individuals is that, in 
their case, EUS is being used as a surveillance tool.  The procedure was originally created as a 
diagnostic tool for confirmation of pancreatic abnormalities.  So while it is the same procedure 
being performed, it is being used in two different circumstances. 
Although EUS is considered the gold standard at some institutions, it does have some 
limitations.  The procedure requires sedation, because of the invasive scope used (Canto et al., 
2004).  If the lesion is not within centimeters of the luminal GI tract, it may not be accessible by 
EUS.  Other limitations of EUS can be seen in individuals with pancreatitis.  Searching for small 
abnormalities in a pancreas with severe pancreatic parenchyma could be difficult (Larghi et al., 
2009).  EUS is also a subjective test, and different readings may be seen between even the most 
experienced sonographers.  There are cases where resection was ordered on a mass that ended up 
being a benign lesion (Larghi et al., 2009).  This has happened more in individuals who have 
witnessed the ravages of terminal pancreatic cancer in their relatives and pushed for resection out 
of fear (Larghi et al., 2009).   
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Other imaging techniques have also been suggested, including MRI, CT, and endoscopic 
retrograde cholangiopancreatography (ERCP). CT can identify only lesions greater than two 
centimeters (Stoita et al., 2011).  Overall, EUS and MRI can detect pancreatic lesions better than 
CT (Canto et al., 2012).  None of these imaging studies has been shown to detect small tumors in 
asymptomatic patients (Brand et al., 2007; Poley et al., 2009).  ERCP does have a three to five 
percent risk for procedure-related acute pancreatitis.  Biomarker tests have also been suggested.  
CA 19-9 was originally used as a management tool for individuals with pancreatic cancer 
(Goonetilleke et al., 2007).  However in the asymptomatic population, CA 19-9 is neither 
specific nor sensitive enough to be used as a sole surveillance tool (Stoita et al., 2011).  At this 
point in time, EUS may currently be the most promising imaging modality for surveillance of 
these high-risk individuals (Larghi et al., 2009).  The procedure has a sensitivity of 84% and a 
specificity of 92% (Stoita et al., 2011). 
It has been suggested that certain steps be taken in order to improve early detection strategies 
(Brand, 2011): 
1. Better define the high-risk populations where the positive predictive value of 
advanced precursor lesions warrants close monitoring with costly and invasive 
testing.  A positive predictive value is the proportion of individuals with a positive 
test result who are correctly diagnosed. 
2. Better understand the pathogenesis of pancreatic cancers. 
3. Create methods that can reliably detect advanced precursor lesions (PanIN) or predict 
when IPMNs will progress to adenocarcinomas. 
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4. Determine whether early detection strategies may appear to improve survival by 
identifying pancreatic cancer earlier in the disease course, when it may be more 
treatable.   
The ultimate goal of surveillance is early detection that will ultimately lead to surgical resection.  
Surgery is the only potentially curative treatment for pancreatic cancer.  The prognosis is most 
favorable with indicators that include a tumor size of less than three centimeters, the ability to 
excise with negative resection margins, negative nodal involvement, and the absence of vessel 
invasion (Yoshizawa et al., 2011).  It has also been found that the quality of life is highest 
amongst patients who had a pancreaticoduodenectomy, also known as the Whipple procedure 
(Yoshizawa et al., 2011).  Overall, surveillance for high-risk individuals has a yield of 
approximately 8%, with the highest yield seen in high-risk patients over the age of 65 (Ludwig et 
al., 2011).  
2.4.3 Implementing Surveillance 
Wide variability is seen with the onset of pancreatic cancer when comparing hereditary cancer 
syndromes, so when to start surveillance has also been debated.  The earliest onset is associated 
with PJS syndrome.  These families are more likely to develop associated cancers at a younger 
age, so surveillance generally begins between 25 and 30 years of age (van Lier et al., 2010).  
FPC families tend to begin surveillance around the age of 40, or 10 years before the earliest 
diagnosis in the family.  But anticipation has also been noted in these families, where this 
regimen may not capture some family members (Larghi et al., 2009). 
Current recommendations, like those for FPC, suggest starting surveillance at age 40, or 
ten years before the earliest diagnosis in all high-risk families excluding PJS.  However, these 
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recommendations do not take into account coexisting risk factors, like smoking or diabetes 
mellitus.  In FPC and hereditary pancreatitis families, smoking can hasten the age of onset by 
one to two decades (Larghi et al., 2009).   
In asymptomatic individuals, it has been recommended that surveillance use a yearly 
follow-up plan.  If an abnormal finding is seen, surveillance may be increased to every three to 
six or three to twelve months (Matsubayashi, 2011).  Slow growing tumors, such as IPMN, may 
require increased surveillance every three to six months.   
2.4.4 Genetic Counseling 
Cancer risk assessment in conjunction with genetic counseling is the process of identifying and 
counseling individuals who are at an increased risk for developing cancer based on pedigree 
analysis, genetic risk models, biochemical tests, physical characteristics (when necessary), and 
imaging, to identify potential hereditary cancer syndromes in a family (Riley et al., 2011).  
Several studies have looked at the impact of genetic counseling for breast cancer from the 
patient’s perceptive (Braithwaite et al., 2004; Meiser et al., 2002).  The overall theme of these 
studies is that genetic counseling for hereditary breast cancer increases accuracy of cancer risk 
perception and decreases overall anxiety in the high-risk population. 
2.4.4.1 Genetic Counseling for Pancreatic cancer 
The effectiveness of genetic counseling has come into question for diseases where the causative 
gene has not been identified, as with hereditary pancreatic cancer (Axilbund et al., 2005).  
Effectiveness of genetic counseling is defined by Axilbund et al., as how well the counseling 
increases risk perceptions and decreases generalized anxiety.  While other cancer syndromes 
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have been identified that carry an increased risk for pancreatic cancer, a single gene has not been 
identified that would predispose to familial pancreatic cancer.   
Early data show that genetic counseling may be effective in preventing an increase in 
psychosocial distress (Maheu et al., 2010).  It is recommended that a complete family history be 
taken to identify any family members with the potential to carry a gene of one of the known 
hereditary cancer syndromes (Brand et al., 2007).  In the absence of a known hereditary 
syndrome, information should be given to families regarding potential cancer risks, given the 
family history.  Genetic counselors play a key role in communicating potential clinical research 
protocols that may include new surveillance options (Axilbund et al., 2005).  Although this 
information may be lacking when compared to other, well-studied cancer syndromes, individuals 
tend to appreciate the information provided during a genetic counseling session (Axilbund et al., 
2005). 
2.4.4.2 UPMC High-Risk Pancreas Clinic 
The University of Pittsburgh Medical Center (UPMC) High-Risk Pancreas Clinic is under the 
direction of Dr. Randall Brand and his genetic counselor, Sheila Solomon, MS, CGC.  The goal 
of the clinic is provide specific risk assessment for pancreatic cancer and prevention and 
surveillance options to individuals.   
 All patients are seen at the clinic through some type of referral.  Most often, these 
referrals come from a patient’s primary care physician, oncologist, genetic counselor, or other 
family member.  Once a referral has been received, patients are scheduled for a clinic visit, 
which is held twice a week at UPMC Shadyside. 
 Patients are first seen by the genetic counselor for the intake.  This includes gathering the 
patient’s medical and family history, explaining potential genes that could be involved, the 
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function of genes and chromosomes, and cancer risks.  The structure of the genetic counseling 
session is similar to a general cancer genetics counseling session, with particular emphasis on 
hereditary syndromes of the pancreas.  An assessment of the family is done to identify if a 
hereditary predisposition to pancreatic cancer may exist.  Once the counseling portion is 
completed, Dr. Brand speaks to the patients from the medical approach.  He discusses whether or 
not he is suspicious for a hereditary predisposition to pancreatic cancer.  If so, potential genetic 
testing is discussed if an identified gene exists for the syndrome in question.  Lastly, he discusses 
the current status of prevention and surveillance.  At the time of recruitment, the current 
prevention recommendations included smoking cessation, a healthy diet, weight loss if 
necessary, regular exercise, and 2000IU Vitamin D (Stolzenberg-Solomon et al., 2010).  Dr. 
Brand also discusses endoscopic ultrasound.  He explains the way the outpatient procedure 
works, what the patients can expect before and after the procedure, and the benefits and 
limitations. At this point, the patient would decide whether or not to proceed with scheduling the 
procedure.  Lastly, Dr. Brand’s research coordinators invite the patients to participate in his 
research studies, including the PAGER study. 
2.4.5 Emotional Impact of Surveillance and Genetic Counseling 
Numerous studies (Bjorvatn et al., 2007; Keogh et al., 2011; Price et al., 2007) have looked at 
risk perception and the level of worry in the more common hereditary cancer syndromes, like 
hereditary breast and ovarian cancer syndrome and hereditary non-polyposis colorectal cancer 
syndrome.  Bjorvatn et al. conducted a study that explored how patients felt about their risk for 
developing cancer and their level of worry.  Their study included patients with a family history 
of a first- or second-degree relative with breast cancer, colon cancer, or a combination of the 
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two.  The study concluded that the patients’ perceived risk decreased after genetic counseling 
(Bjorvatn et al., 2007).  It was thought that this decrease could be due to a preconceived idea of 
their risk before counseling based on their personal experiences.  This study also asked patients 
to recall information about the surveillance options that were available to them.  Twenty-seven 
percent of participants in this study gave incorrect answers when asked about inclusion in a 
surveillance program (Bjorvatn et al., 2007).  This may have been due to the fact that 
surveillance was not a main focus of the counseling session, which is different from the UPMC 
High-Risk Pancreas Clinic.  Overall, this study showed that the level of worry was reduced after 
one genetic counseling session (Bjorvatn et al., 2007).   
Keogh et al. conducted a study in 2011 aimed at describing the risk perception and 
screening behavior of women who were at an increased, but unexplained familial risk for breast 
cancer.  The study included women with at least one first- or second-degree relative with breast 
cancer under the age of 50.  Women who had a BRCA mutation in their family were excluded.  
During analysis, researchers found that perceived risk could not be separated from their 
emotional response to their risk.  Through interviews with participants, risk perception was 
defined as a layered concept.  It included their understanding of heredity, risk factors, genetics 
and popular discourses (Keogh et al., 2011).  These women felt a sense of the social expectations 
about how they should interpret and manage their risk.  They felt they had to justify their 
thoughts that may have been inconsistent with their actions, including surveillance (Keogh et al., 
2011). 
A third study, conducted by Price et al., aimed to identify predictors of cancer worry in 
high-risk, unaffected women in breast cancer families.  Participants of this study included 
unaffected women with a significant family history of breast or ovarian cancer, or a documented 
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BRCA mutation in the family.  Overall, the study showed that the level of worry in these women 
was generally low, despite reporting their perceived risk of developing breast cancer as 50% 
(Price et al., 2007).  A woman’s worry about breast cancer is influenced by a range of factors 
including risk perception, and that her personal experiences have an independent affect on worry, 
asides from her own sense of risk (Price et al., 2007).  The strongest predictor of worry was 
general anxiety and may be due to the woman’s personal experience with familial breast cancer. 
Little is known about the effect of surveillance and genetic counseling on the well-being 
of those at high risk for pancreatic cancer (Hart et al., 2011).  As shown above, extensive studies 
have been done on the effective outcome of genetic counseling in the more common high-risk 
cancer syndromes, like breast, ovarian, and colon (Braithwaite et al., 2004; Ellen et al., 2008; 
Keller et al., 2008; Meiser et al., 2002).  Unfortunately, these same studies have not been 
conducted in large numbers for individuals at risk for pancreatic cancer.  It has been found that 
pancreatic lesions are more common in the high-risk populations (Canto et al., 2012).  The issue 
then becomes which ones warrant surgical resection and which ones can be followed by 
surveillance.  Experts anticipate that there will be a positive impact on a patient’s level of cancer 
worry once surveillance and prevention strategies are shown to be effective (Maheu et al., 2010). 
Studies have been conducted on the value of genetic counseling for FPC kindreds.  
Overall, individuals felt that genetic counseling was valuable, despite the lack of genetic testing 
for a causative gene (Axilbund et al., 2005).  However, in this same study patients reported 
frustration with the genetic counseling session because of the lack of current knowledge.   
Studies have also evaluated individuals’ perceived cancer risk and how genetic counseling 
impacted their perception of risk.  Overall, patients at all cancer risk levels tended to 
overestimate their pancreatic cancer risk, and their view was not greatly influenced by genetic 
 25 
counseling (Axilbund et al., 2005).  This may be due to younger individuals with a strong family 
history of pancreatic cancer who have watched multiple family members fighting the disease 
(Maheu et al., 2010).  This may also be due to the fact that there are no pancreatic cancer 
survivors in the family.  This is in contrast to other hereditary cancer syndromes, where there 
may be family members who have survived their cancer diagnosis. 
2.5 HEALTH BELIEF MODEL 
The Health Belief Model (HBM) is a theoretical construct that has served as a framework in 
studies to explain asymptomatic individuals’ uptake of cancer surveillance (Lewis et al., 2009).  
It is one of the oldest and most widely used conceptual frameworks of health behavior (Guvenc 
et al., 2010).  Initially introduced by Hochbaum et al. in the 1950s, the model focuses on four 
main concepts: susceptibility, seriousness, benefits, and barriers.  Perceived susceptibility is an 
individual’s perception of his likelihood of experiencing a condition that would adversely affect 
his own health.  Perceived seriousness is a person’s interpretation of the degree of intensity of a 
particular disease.  Perceived benefits are a person’s assessment of the positive consequences of 
adopting the behavior.  Perceived barriers are the individual’s assessment of the influences that 
facilitate or discourage the promoted behavior  
The framework states that an individual’s health behavior will be the result of the 
personal cost-benefit analysis based on these concepts.  Studies have been performed using 
HBM, looking at individuals’ willingness to have surveillance for pancreatic cancer.  In 2009, 
Lewis et al. found that the individuals who were most motivated to have surveillance were those 
that had the greatest overall perceived risk for all types of cancers (e.g. those in the breast cancer 
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group who had a personal history and those in the pancreatic cancer sub-groups).  Overall, the 
HBM has generated research regarding behaviors for health maintenance or prevention of 
disease in the healthy population (Champion, 1984).  
The HBM has been revised by Victoria Champion to measure the constructs as it relates 
to breast cancer and surveillance behavior (Champion, 1984, 1985, 1993, 1999).  A questionnaire 
was created to test the main constructs for validity and reliability.  These scales were then termed 
Champion’s Health Belief Model (CHBM) scales (Champion & Scott, 1997).  The goal of these 
scales was to create an instrument that would be both reliable and valid and could be consistently 
used (Champion, 1993).  Champion created these scales by measuring the uptake of breast 
examinations in women.  Her study found that there is a point at which individuals will pursue 
particular cancer surveillance.  This is most apparent when an individual perceives his risk as 
high and perceives the barriers as low (Lewis et al., 2009).  Since then, the construct of her 
model has been modified to evaluate the cancer surveillance uptake for different cancer 
screenings, for use in other countries, and with different ethnicities. She has also evaluated the 
mammography uptake in African American women (Champion et al., 2008).  Other researchers 
have translated the validated questionnaire for use in assessing the uptake of breast cancer 
surveillance in non-English speaking countries (Gozum et al., 2004; Medina-Shepherd et al., 
2010; Taymoori et al., 2009).   In all of these studies, the CHBM scales have been validated.  In 
addition to its use in other languages, the CHBM scales have also been validated in the study of 
other cancer surveillances.  The uptake of colonoscopies and pap smears has been studied using 
the CHBM scales (Guvenc et al., 2011; Mitchell et al., 2011).  All validated studies have shown 
this same relationship between uptake of a particular surveillance method when the perceived 
risk is high and perceived barriers are low.  In addition, these studies all show when individuals 
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believe the surveillance method is beneficial, they have less fear about the procedure itself.  
While the CHBM scales have been used in other surveillance procedures, this is its first known 
use for pancreatic cancer surveillance and its psychosocial impact. 
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3.0  AIM OF STUDY 
The aim of this study is to identify individuals’ top motivation for attending the high-risk 
pancreas clinic.  In addition, for those high-risk individuals who elect to have the endoscopic 
ultrasound, the study will examine their perceptions of cancer risk and cancer worry before and 
after the endoscopic procedure. 
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4.0  METHODS AND PROCEDURES 
This study was implemented as a modification to the current protocol, The Pancreatic 
Adenocarcinoma Gene Environment Risk (PAGER) study – A prospective cohort study of 
patients at risk or having pancreatic disease.  The addition of the questionnaires was reviewed 
and approved by the University of Pittsburgh Institutional Review Board (MOD07030072-28), 
which can be seen in Appendix A. 
4.1 PARTICIPANTS 
Study participants were recruited through their involvement in the PAGER study.  Once enrolled 
in PAGER, individuals were approached about their participation in this study.  Patients were 
seen at either the UPMC Shadyside or the UPMC Presbyterian Gastrointestinal (GI) Labs for 
EUS.  Three separate groups were formed depending on their status: initial visits, return visits, 
and comparisons.  Patients in the initial visit and return visit groups were considered the case 
cohort for this study.  Participants in the initial visit category were those attending the genetic 
counseling clinical appointment due to a family history of pancreatic cancer and were counseled 
about having endoscopic ultrasound surveillance for the first time.  They were scheduled or had 
their initial EUS when first enrolled into this study.  Individuals in the return visit group were 
those who were identified as high-risk due to a family history of pancreatic cancer and who had 
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already had at least one endoscopic ultrasound.  These individuals were counseled previously 
and were having follow-up EUS at the time they were enrolled in this study. Participants in the 
comparison group were those who had been identified as having any signs or symptoms relating 
to the pancreas, which prompted their physician to order a diagnostic EUS.  Once enrolled, all 
patients were given a de-identified code to track their questionnaires.  All IDs started with PA to 
signify that they were part of the PAGER study and then a number that was specific to them. 
4.2 INSTRUMENT 
4.2.1 Validation 
The content, format, and validity of the questionnaires were developed based on the Champion 
Health Belief Model (CHBM) scales.  Questions were constructed using input from the CHBM 
scales for breast and cervical cancer (Guvenc et al., 2010).  Changes in wording were made to 
make items applicable to pancreatic cancer and surveillance, but the overall theme of each 
question was kept intact. 
4.2.2 Questionnaires 
We developed the “Feelings about Cancer Risk and Endoscopic Ultrasound” Questionnaire 
based on a review of current literature.  The survey instrument consisted of 16 questions, divided 
into five sub-categories: level of worry, risk perception, family history, social support, and health 
intervention.  The questionnaire had four questions addressing the individuals’ level of worry, 
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six questions addressing their risk perception, two questions concerning their family history, two 
questions about the individuals’ social support, and two questions addressing the health 
intervention.  Individuals were asked to assess their feelings about each question using a Likert 
scale.  The scale gave individuals the chance to strongly disagree (1), disagree (2), neutral (3), 
agree (4), and strongly agree (5) with each statement.  Questions addressing family history did 
not pertain to the comparison cohort, so a N/A (0) option was also available.  High-risk 
individuals (cases) were asked an additional five questions, used to assess their referral route, 
motivation for seeking genetic counseling and EUS, whether or not they decided to pursue an 
EUS, and whether or not their feelings about their cancer risk or their level of worry changed 
since their first EUS.  Each questionnaire also had a section where participants could write any 
additional comments for the researchers.  Questionnaires can be seen in Appendix B. 
All participants, regardless if they were a case or comparison, were given two 
questionnaires as part of their enrollment.  Both questionnaires used the same questions to allow 
for analysis.  For case participants, the first questionnaire was given either at the conclusion of 
the genetic counseling appointment while the patient was in the office or during their pre-op time 
in the GI Lab.  Participants were asked to complete the questionnaire before leaving the 
counseling session or being taken in for their procedure.  Before the case participant was taken 
for EUS, the second questionnaire was placed with their personal belongings or with a family 
member or friend, along with a self-addressed stamped return envelope.  Participants were asked 
to complete the second questionnaire after the procedure and return it upon completion.  
 32 
4.3 DATA COLLECTION 
Data were collected between September 2011 and March 2012.  Questionnaires took 
approximately five to ten minutes to complete.  Data input occurred as the second questionnaires 
were received.  Fifteen of the 20 (75%) participants returned the second questionnaire.  Those 
who did not immediately return the second questionnaire were contacted after a period of time.  
At that point, if the individuals were still interested in participating, then the questionnaire was 
either emailed to them for completion, or the questions were read aloud to them over the phone.  
Along with the information gathered through their answers, information was also gathered about 
the participant’s demographics.  Information including the participants’ age, gender, ethnic 
background, and EUS findings were collected.  For the high-risk individuals, family history and 
genetic status were also collected.   
4.4 DATA ANALYSIS 
The results of this study were analyzed using three different methods.  The majority of the data 
was collected using the answers from the Likert scale portion of the questionnaire.  Descriptive 
statistics was used for this data.  It is a method typically used for smaller studies as a way to 
quickly display and interpret the data (Rosner, 2011).  Using this method, researchers can 
conclude what trends may warrant a more detailed look in future research studies.  Data was 
inputted into an Excel spreadsheet and the mean value was calculated for each question.  Charts 
were created to keep the data as self-contained as possible, which is the preferred method when 
using descriptive statistics (Rosner, 2011).  For this study, the arithmetic mean was used to 
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evaluate the trends for each question.  It was determined that the mean was the most logical way 
to analyze the data because the data was less likely to be affected by extreme values, which is a 
limitation of the arithmetic mean.  Trends were recorded from the arithmetic mean and noted for 
any score change. 
 To evaluate for statistical significance, the two cohorts were combined to give a larger 
sample size.  A one-tailed t-test was performed on the combined data to assess the significance 
before and after the procedure (Rosner, 2011).  For this study, a critical value of 0.05 was used to 
test for significance.  
The narrative responses were analyzed by thematic analysis.  This method is used for 
open-ended responses by participants when a clear answer is not apparent, as in a numeric 
response (Braun and Clark, 2006).  It is usually chosen as an analytic method because it is more 
flexible and relatively easy for a researcher to learn.  However, limitations of thematic analysis 
are that the methodology is not well defined and thus open to interpretation.  For the responses 
received, thematic analysis is the method most applicable.   Within the narrative responses, 
themes were noted and compared with the overall trends from the descriptive statistical analysis 
to see if any similarities were seen.  This study may act as a pilot for a future, larger study, in the 
hopes of including more families at high risk so that the results may reach statistical significance. 
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5.0  RESULTS 
5.1 SAMPLE DESCRIPTION 
A total of 33 individuals (20 cases and 13 comparisons) provided informed consent for this 
study.  With a combination of returned questionnaires and follow-up phone calls, 26 participants 
completed both questionnaires (15 cases and 11 comparisons) for an overall complete 
participation rate of 87%.  Demographic, family medical history, and pertinent personal medical 
information were recorded for these individuals. 
The average age of the case individuals was 58.4 years, with a range of 35 – 74 years.  
Seventy-three percent of the cases were female, and all individuals reported race as Caucasian.  
Genetic status and family history of these cases were also recorded.  Complete pedigrees of these 
15 cases can be found in Appendix D.  Two carried mutations in CKDN2A (p16) and had an 
extensive family history of pancreatic cancer.  Two carried mutations in BRCA1, both of whom 
had first-degree relatives with pancreatic cancer.  One case individual carried a maternally 
transmitted BRCA2 mutation, though her father had pancreatic cancer.  Two case individuals 
were diagnosed with Lynch syndrome; one carried an MSH6 mutation and the other carried an 
MSH2 mutation.  There were two cases with strong family history but no known gene mutation.  
In these families, one case was tested and not found to carry a BRCA mutation; in the other 
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family, a sister of the proband tested negative for BRCA mutation.  All other cases were 
diagnosed with FPC.  There were no cases in this study that came from the same kindred.   
EUS findings were also recorded.  A short description of the EUS findings can be found in 
the table below.   
Table 1. EUS findings from case cohort 
STUDY NUMBER GENETIC STATUS EUS FINDINGS 
PA1652 BRCA2+ 12mm cystic lesion, IPMN 
PA1324 FPC Subtle nodular change 
PA0469 FPC Multi-focal cysts, not malignant 
PA0998 FPC 4x3mm cystic lesion, not malignant 
PA1091 BRCA- sister 24mm benign lipoma 
PA0557 MSH6+ Multiple cystic lesions 
PA0486 BRCA- Premalignant IPMN 
PA0527 p16+ 2 small cystic lesions 
PA1559 p16+ 5mm lesion 
PA1680 FPC Normal pancreas 
PA0296 FPC 2x1mm cystic mass 
PA1087 MSH2+ Normal pancreas 
PA0892 BRCA1+ Normal pancreas 
PA1027 BRCA1+ Normal pancreas 
PA1729 BRCA testing not covered Pancreas cyst vs. pseudocyst 
 
The average age of the comparison group was 67.4 years, with a range of 53 – 90 years.  Sixty-
four percent of the comparisons were female and all individuals were Caucasian.  The EUS 
findings were also recorded to assess medical indication and outcome.  A short description of 
those findings can be found in the table below. 
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Table 2. EUS findings from comparison cohort 
STUDY NUMBER EUS FINDINGS 
PA1597 36x25mm cyst, not malignant 
PA1679 5x4mm cystic lesion 
PA1596 Large cyst, not malignant 
PA1705 Mild dilation of main pancreatic duct 
PA1743 Negative for chronic pancreatitis 
PA1763 25mm IPMN 
PA1828 Serous cystadenoma 
PA1880 Pancreatic mass 
PA1883 Pancreatic mass 
PA1852 Small neuroendocrine tumors 
PA1750 Large cystic lesion, no solid component 
5.2 SUPPLEMENTAL QUESTIONNAIRE 
High-risk individuals were also given a supplemental questionnaire that contained five 
questionnaires to assess specific topics in that population.  Of the 15 high-risk individuals in this 
study, five participants were being evaluated for the first time, and ten were returning for follow-
up surveillance.  All 15 individuals were asked how they found out about genetic counseling for 
high-risk families.  Six indicated they were referred through their doctor.  Three individuals said 
a family member informed them.  Three indicated another route not given as a choice.  
Participants were permitted to choose more than one option.  One heard of counseling from his 
family and physician, one indicated both the Internet and doctor, and the last heard of genetic 
counseling through the Internet and a second unidentified option.  All individuals were also 
asked what their top motivation was for seeking genetic counseling for pancreatic cancer.  Ten 
individuals indicated they were looking for information related to their personal risk for 
pancreatic cancer.  One participant was looking for risk information related to her family.  One 
individual was concerned that he had pancreatic cancer and was looking for a diagnosis.  Two 
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individuals indicated they wanted information about their personal risk as well as information for 
the entire family.  One individual was using the session for familial information and as a means 
of having the EUS. 
Initial participants who were being seen at the genetics clinic were also asked if they 
would be having the EUS after hearing the information in the session.  All five individuals 
elected to schedule their EUS procedure after the genetic counseling session.  Thus, the second 
question was not applicable. 
The ten returning individuals were asked to recall how the EUS affected their level of 
worry and cancer risk perception since they had their first EUS.  Three participants indicated that 
their level of worry and cancer risk perception had decreased since they started surveillance.  
One participant indicated his worry level and risk perception had both increased since starting 
EUS.  Five individuals indicated both aspects had remained the same since starting the protocol.  
And one individual indicated that while her cancer risk perception had remained the same, her 
level of worry increased. 
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Table 3. Supplemental questionnaire answers 
QUESTION INITIAL VISITS (# of participants) 
RETURN VISITS 
(# of participants) 
How did you find out about 
genetic counseling for 
individuals with a family of 
pancreatic cancer?  
Family = 2 
Doctor = 3 
Family = 1 
Doctor = 3 
Other = 3 
Family and Doctor = 1 
Doctor and Internet = 1 
Internet and Other = 1 
What was your top motivation 
for coming to the Pancreas 
Clinic? 
Personal cancer risk = 4 
Cancer risk for family = 1 
Personal cancer risk = 6 
Find out if I have cancer = 1 
Personal and Family risk = 2 
Family and to have EUS = 1 
Are you going to have the 
endoscopic ultrasound? 
Yes = 5  
How has your you feeling about 
your cancer risk and worry 
changed from the first time you 
had an EUS? 
  Both decreased = 3 
Both stayed the same = 5 
Both increased = 1 
Risk perception increased, worry 
stayed the same = 1 
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5.3 ANALYSIS OF CASES VERSUS COMPARISONS 
The first section of analysis focuses on the trends of the two participant groups.  The trends were 
scored for each question before and after the endoscopic ultrasound. 
5.3.1 Level of worry 
Table 4 shows the data on level of worry for both cases and comparisons.  An average was 
calculated for both groups. 
Table 4. Cases versus comparisons level of worry 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
I feel I will get pancreatic cancer 
some time during my life. 2.93 1.72 2.93 1.95 
The thought of pancreatic cancer 
scares me. 3.73 4.55 4.13 4.27 
I worry more about my risk since 
watching family members fight 
pancreatic cancer. 
4.20 0.64 4.00 0.55 
I am afraid of the endoscopic 
ultrasound, for fear of a bad result. 1.73 2.45 1.60 2.00 
LEGEND N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Both groups showed a decreased trend in their fear of the procedure itself.  The cases group had 
a decrease of 0.13, while the comparison group had a decrease of 0.45.   
In contrast, the groups showed opposing trends when asked about their fear of a 
pancreatic cancer diagnosis.  The case group increased by 0.40 after the procedure, while the 
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comparison group decreased 0.28.  The comparison group also scored higher, overall, than the 
case group. 
5.3.2 Risk perception 
Table 5 shows the data on the cancer risk perception for both populations.  Averages were 
calculated for both groups. 
Table 5. Cases versus comparisons risk perception 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
If I develop pancreatic cancer, I will 
not live longer than 1 year. 2.80 3.27 2.73 2.91 
I understand the benefits and 
limitations of the endoscopic 
ultrasound. 
4.27 3.36 4.33 3.27 
I have control over my pancreatic 
cancer risk by having the endoscopic 
ultrasound. 
2.87 2.91 3.40 3.73 
Having the endoscopic ultrasound 
can find pancreatic cancer early. 4.27 3.91 4.33 3.64 
If my pancreatic cancer is found 
early because of the endoscopic 
ultrasound, I will live longer. 
4.07 3.09 3.83 3.77 
Having the endoscopic ultrasound 
gives me the feeling of a lower risk 
for pancreatic cancer. 
3.20 3.18 3.47 3.82 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Three of the questions related to the individuals’ view on their cancer risk had a notable trend.  
The question related to the control a person has over their cancer risk.  Both groups seemed to 
feel they had more control over their risk after the EUS.  The case group’s mean increased by 
0.53 while the comparisons’ mean increased by 0.82.  Both groups also shared a similar trend 
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regarding the perception that the EUS gives them a feeling of a lower cancer risk.  The cases’ 
score increased by 0.27, while the comparisons’ score increased 0.64.   
For the question pertaining to life span as it relates to early diagnosis by EUS, the case 
group trended slightly lower after the EUS, with a decrease of 0.24.  However, the comparisons 
had a trend that moved in the opposite direction.  The comparisons’ mean increased after the 
EUS by 0.68.   
5.3.3 Family history 
Table 6 shows the data on the impact of family history for both cases and comparisons.  An 
average was calculated for both groups. 
Table 6. Cases versus comparisons family history 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
Having family members with 
pancreatic cancer increases my 
chance to develop it. 
4.47 1.18 4.33 1.55 
I want to encourage family members 
to have the endoscopic ultrasound. 4.20 3.81 4.33 2.45 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
As expected, family history seemed to hold one of the biggest trend differences between the two 
groups.  The comparison cohort had a decrease of 1.36 when asked if they will encourage other 
family members to pursue EUS.  This is compared to a steady trend for the case cohort before 
and after the procedure. 
 42 
5.3.4 Social Support 
Table 7 shows the data on social support for both populations.  Averages were calculated for 
both groups. 
Table 7. Cases versus comparisons social support 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
My family encouraged me to have 
pancreatic cancer surveillance. 3.27 1.36 3.40 1.09 
If I get pancreatic cancer, I do not 
want to be a burden on my family 4.00 4.27 4.13 4.18 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Social support is an important aspect to pancreatic cancer, because of the seriousness of the 
disease and the impact it can have on an entire family.  As expected, the encouragement of 
family members showed a trend difference between the two groups.  While the score change 
before and after the procedure was not notable, the overall score difference shows the trend 
difference between the two populations.  The cases trended almost two points higher than the 
comparisons in both questionnaires.  
As expected, both groups responded to the impact the disease has on the family once a 
diagnosis has been made.  This relates to the perceived seriousness of pancreatic cancer and is 
noted in the high trend numbers from both groups for both questionnaires. 
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5.3.5 Health Intervention 
Table 8 shows the data on health intervention for both cases and comparisons.  An average was 
calculated for both groups. 
Table 8. Cases versus comparisons health intervention 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
I want to do everything I can to 
prevent pancreatic cancer. 4.73 4.91 4.67 4.82 
If developing pancreatic cancer is in 
my future, then having the 
endoscopic ultrasound will not 
change that. 
2.27 2.91 3.07 2.64 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Both groups responded highly to the use of EUS for medical intervention purposes.  We would 
not expect this data to be any lower as these individuals are those that are pursuing EUS.  There 
was an opposite trend noted in the final question in this group.  The question acknowledges the 
idea of a potential barrier in the high-risk population.  The cases trended higher after the EUS 
(0.80), while the comparisons had a decrease in trend (0.27) after the procedure. 
5.4 ANALYSIS OF FAMILIAL CASES BY MUTATION STATUS 
The following portion is an evaluation of the trends before and after the endoscopic ultrasound of 
only the familial patients.  The familial patients were divided into two groups, those with an 
identified germline mutation and those without a germline mutation. In this section, the 
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abbreviation “with” in the tables signifies those familial patients with an identified germline 
mutation and “without” signifies the familial patients without an identified germline mutation. 
5.4.1 Level of worry 
Table 9 shows the data on level of worry for both familial cases with and without a germline 
mutation.  An average was calculated for both groups. 
Table 9. Familial level of worry 
 BEFORE EUS AFTER EUS 
 WITH WITHOUT WITH WITHOUT 
I feel I will get pancreatic cancer 
some time during my life. 2.71 3.12 3.45 3.00 
The thought of pancreatic cancer 
scares me. 3.29 4.13 3.86 4.38 
I worry more about my risk since 
watching family members fight 
pancreatic cancer. 
4.00 4.38 3.86 4.13 
I am afraid of the endoscopic 
ultrasound, for fear of a bad result. 1.86 1.63 1.71 1.50 
LEGEND N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Increased trends were seen with both populations when asked about their fear of pancreatic 
cancer after the endoscopic ultrasound.  Those with a germline mutations increased by 0.57, 
while those without a germline mutation increased by 0.25.  It is also important to note the 
overall score difference between the two groups.  Although those without a mutation increased 
by a smaller amount, their overall score was higher than those with a mutation. 
 Opposing trends were noted when asked about their worry about developing pancreatic 
cancer at some point in their lifetime.  Those with a germline mutation increased by 0.74, while 
those without an identified mutation decreased by 0.12. 
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5.4.2 Risk perception 
Table 10 shows the data on the cancer risk perception for both populations.  Averages were 
calculated for both groups. 
Table 10. Familial risk perception 
 BEFORE EUS AFTER EUS 
 WITH WITHOUT WITH WITHOUT 
If I develop pancreatic cancer, I will 
not live longer than 1 year. 2.29 3.25 2.43 3.00 
I understand the benefits and 
limitations of the endoscopic 
ultrasound. 
4.43 4.13 4.43 4.25 
I have control over my pancreatic 
cancer risk by having the endoscopic 
ultrasound. 
3.29 2.50 3.86 3.00 
Having the endoscopic ultrasound 
can find pancreatic cancer early. 4.43 4.13 4.29 4.38 
If my pancreatic cancer is found 
early because of the endoscopic 
ultrasound, I will live longer. 
3.86 4.25 3.79 3.88 
Having the endoscopic ultrasound 
gives me the feeling of a lower risk 
for pancreatic cancer. 
3.00 3.38 3.29 3.63 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Both populations felt they had more control over their cancer risk by having EUS.  Those 
individuals with a mutation increased by 0.57 and those without increased by 0.50.  Both 
populations also felt the procedure gave them the feeling of a lower cancer risk.  Mutation 
carriers increased by 0.38 after the procedure and those without an identified mutation increased 
by 0.25.  Both groups were also asked if they would live longer if pancreatic cancer were found 
by EUS.  Those individuals with a mutation decreased by 0.07, and those without a mutation 
decreased by 0.37. 
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5.4.3 Family history 
Table 11 shows the data on the impact of family history for both familial cases with and without 
a germline mutation.  An average was calculated for both groups. 
Table 11. Familial family history 
 BEFORE EUS AFTER EUS 
 WITH WITHOUT WITH WITHOUT 
Having family members with 
pancreatic cancer increases my 
chance to develop it. 
4.43 4.50 4.43 4.25 
I want to encourage family members 
to have the endoscopic ultrasound. 4.38 4.13 4.43 4.25 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Both populations were asked about the impact of a family history of pancreatic cancer on their 
individual pancreatic cancer risk.  Those individuals with a germline had stable score, while 
those without a germline mutation decreased by 0.25. 
5.4.4 Social Support 
Table 12 shows the data on social support for both populations.  Averages were calculated for 
both groups. 
Table 12. Familial social support 
 BEFORE EUS AFTER EUS 
 WITH WITHOUT WITH WITHOUT 
My family encouraged me to have 
pancreatic cancer surveillance. 3.00 3.50 3.57 3.25 
If I get pancreatic cancer, I do not 
want to be a burden on my family 3.86 4.13 3.86 4.38 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
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Opposing trends were noted when asked whether or not their family encouraged them to have 
EUS.  Those with a germline mutation increased by 0.57 after the procedure, while those without 
a mutation decreased by 0.25. 
5.4.5 Health Intervention 
Table 13 shows the data on health intervention for both familial cases with and without a 
germline mutation.  An average was calculated for both groups. 
Table 13. Familial health intervention 
 BEFORE EUS AFTER EUS 
 CASES COMPARISONS CASES COMPARSIONS 
I want to do everything I can to 
prevent pancreatic cancer. 4.71 4.75 4.71 4.63 
If developing pancreatic cancer is in 
my future, then having the 
endoscopic ultrasound will not 
change that. 
2.43 2.13 2.86 3.25 
 
LEGEND 
N/A  
0 
Strongly 
Disagree  
1 
Disagree  
2 
Neutral  
3 
Agree  
4 
Strongly 
Agree  
5 
 
Similar trends were noted when asked about an inevitable pancreatic cancer diagnosis, even with 
EUS.  The familial group with an identified mutation increased by 0.43.  The familial group 
without a mutation increased by 1.12. 
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5.5 ANALYSIS OF COMBINED CASES AND COMPARISONS 
For the purposes of statistical analysis, the case and comparison groups were combined to 
evaluate whether there was any statistical significance pre- and post-procedure.  Table 14 
includes the p-values from the questions before and after the procedure. 
Table 14. T-test analysis of combined groups 
STATEMENT P-value 
I feel I will get pancreatic cancer some time during my life. 0.486 
The thought of pancreatic cancer scares me. 0.649 
If I develop pancreatic cancer, I will not live longer than 1 year. 0.457 
Having family members with pancreatic cancer increases my chance to 
develop it. 0.603 
I want to do everything I can to prevent pancreatic cancer. 0.490 
I worry more about my risk since watching family members fight 
pancreatic cancer. 0.256 
My family encouraged me to have pancreatic cancer surveillance. 0.901 
I understand the benefits and limitations of the endoscopic ultrasound. 1.000 
I am afraid of the endoscopic ultrasound, for fear of a bad result. 0.258 
If developing pancreatic cancer is in my future, then having the 
endoscopic ultrasound will not change that. 0.187 
I have control over my pancreatic cancer risk by having the endoscopic 
ultrasound. 0.047 
Having the endoscopic ultrasound can find pancreatic cancer early. 0.664 
If my pancreatic cancer is found early because of the endoscopic 
ultrasound, I will live longer 0.594 
I want to encourage family members to have the endoscopic ultrasound. 0.471 
If I get pancreatic cancer, I do not want to be a burden on my family. 0.857 
Having the endoscopic ultrasound gives me the feelings of a lower risk 
for pancreatic cancer. 0.1334 
 
Using this statistical method, one question showed statistical significance before and after the 
procedure.  The question with significance less than 0.05 was the question related to the feeling 
of control over the pancreatic cancer risk by having the endoscopic ultrasound. 
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5.6 NARRATIVE RESPONSES 
Both questionnaires gave participants the opportunity to add additional comments in areas they 
felt were not covered.  All comments received were recorded from high-risk patients.  A total of 
eight comments were recorded, including three participants who added comments to both 
questionnaires.  A complete transcription of comments can be viewed in Appendix C. 
All responses were categorized into one of the four Health Belief Model categories.  
PA0486’s comments seemed to address issues related to perceived susceptibility.  She mentions 
that her chances of getting pancreatic cancer are out of her control and she understands her 
inherent susceptibility.  She understands the constant surveillance of her cysts and has had breast 
cancer in the past.  PA1091 touched on the idea of perceived seriousness.  He has a strong family 
history of pancreatic cancer and was relatively scared of the diagnosis.  He indicated that 
pancreatic cancer is a silent killer.  He was comparing warning signs of pancreatic cancer with 
other more common cancers, with more identifiable symptoms.  Four individuals (PA0527, 
PA1729, PA0469, PA0998) gave comments that seemed related to perceived benefits.  All 
individuals felt that early detection of pancreatic cancer was an important aspect of surveillance.  
Some believed in the EUS and it has become part of their lives, since some have had multiple 
surveillance procedures due to a hereditary susceptibility to cancer.  One individual discussed 
that while he sees the benefit in surveillance, he cannot get the rest of his family to even discuss 
it.  He has tried different strategies and cannot “get through to them”.  The last category, 
perceived barriers, encompassed responses from two individuals (PA0215 and PA0557).  Both 
individuals noted that they had pancreatic changes that were not seen on EUS, but on MRI/CT. 
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6.0  DISCUSSION 
Through the use of the Health Belief Model, this study has examined individuals’ motivation for 
attending a high-risk clinic as well as evaluating the pancreatic cancer risk perception and level 
of worry in a high-risk, healthy population.  This is one of the few studies that have looked at the 
psychosocial impacts of the endoscopic ultrasound in this small population.  
The first goal of this study was to identify familial individuals’ top motivation for 
attending the high-risk pancreas clinic.  Most high-risk individuals found out about the clinic 
through either their family or doctor.  This is consistent with how individuals are referred to the 
clinic.  The top motivation for attending the clinic in ten of 15 participants was to find out more 
information about their personal cancer risk.  This is consistent with other studies (Axilbund et 
al., 2005) that showed individuals want information about their cancer risks.  Although this same 
study has shown that individuals were frustrated with the lack of definitive information and 
genetic testing available for some pancreatic cancer kindreds. 
The second goal of this study was to assess the cancer risk perception and level of worry 
before and after endoscopic ultrasound.  Participants were asked questions that evaluated 
different aspects of their worry level.  Both the comparison and case cohorts shared a similar 
trend decrease in regards to their fear of the procedure.  Previous studies have shown this same 
trend, with a decrease in the level of worry, particularly in the unaffected population (Price et al., 
2007).  It seems reasonable that the case cohort would be fearful of the procedure due to the 
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impact of their family history.  It seems the comparison group may have viewed some barriers of 
the procedure.  This is likely due to the fear of a cancer diagnosis as a result.  Going in with a 
suspected pancreatic abnormality for potential diagnosis could have elicited fear about the 
procedure itself. 
Opposing trends were noted in the cohorts when asked about their fear of a pancreatic 
cancer diagnosis.  This was also noted when the familial groups were separated by mutation 
status.  Those without a mutation had a higher overall score than those with a germline mutation.  
The case cohort may still worry about their risk because of their family history.  They have an 
idea of how serious the condition is and are fearful of developing it.  Studies have shown that the 
strongest predictor of cancer worry was a patient’s overall increased anxiety (Price et al., 2007).  
However, this finding seems to be in contrast with other studies evaluating cancer worry.  
Research has shown an overall decrease of cancer worry after genetic counseling and 
surveillance (Keller et al., 2008).  The comparison group followed the trend expected from 
previous research which may be because the diagnostic EUS was negative for pancreatic cancer.  
Overall, the case and comparison cohorts showed similar trends related to the EUS and 
their cancer risk perception.  Participants reported feeling greater control over their pancreatic 
cancer risk by having the EUS.  This was also noted in the familial trend comparisons.  
Additionally, this was the only question that showed statistical significance when both cohorts 
were combined.  This is an important aspect for both populations.  It is possible that an 
individual with a strong family history of a disease or an individual with a pancreatic 
abnormality may feel that they do not have control over their health and are just being told where 
to go for medical advice.  The fact that this procedure seems to have a positive impact on these 
individuals means they might be acknowledging the benefits, even if the medical professionals 
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are still unsure about its validity in certain cases.  This trend is similar to a theme noted in Keogh 
et al.  A group of women at high-risk for breast cancer, for an unknown reason, explained that 
they were concerned about their breast cancer risk and were as vigilant as possible.  Their 
thought process was driven by their concern for their cancer risk and their belief that their actions 
may reduce their risk. 
Participants were also asked a more direct question about their pancreatic cancer risk to 
evaluate their perceived risk.  Participants expressed that this procedure gave them a feeling of a 
lower cancer risk.  They accepted the findings from the EUS as fact: they did not have cancer.  
These similar trend were also noted when the familial groups were divided.  This is consistent 
with previous studies that have noted a lower risk perception after genetic counseling, which 
included a discussion on surveillance (Bjorvatn et al., 2007).   
In regards to the participants’ understanding of the benefits and limitations of the EUS, 
the case and comparison cohorts differed in their trends.  One possible reason for this difference 
is because of the significantly different conversation with each cohort of patients about the 
procedure itself.  The limitations of the EUS are quite different when looking at a potentially 
healthy pancreas as opposed to looking for a suspected pancreatic change.  In the high-risk 
healthy cohort, the limitations are explained in greater detail because the effectiveness of EUS 
for this service is not well understood.  It is unclear whether or not surveillance will improve 
survival, which is something that is not explained to the comparison cohort, since the test is 
being used for diagnostic purposes (Canto et al., 2012; Poley et al., 2009).  For the comparison 
cohort, the limitations are not as extensive because the physician knows what to look for in the 
pancreas.  In addition, the limitations may not be as much of a concern for the comparison cohort 
because they could be facing a cancer diagnosis.  The intricacies of the procedure may not be as 
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much of a concern.  The benefits and positive feelings outweigh the barriers and potential 
limitations of the procedure.  This result is in contrast with previous studies that have found that 
patients could not recall surveillance information and whether or not they had the option of 
surveillance (Bjorvatn et al., 2007).  This study claims that surveillance may not have been a 
main part of the counseling session.  However, the conversations with the patients in this study 
center around surveillance and prevention, since many times genetic testing cannot be offered to 
confirm their true risk.   
Participants were also asked about early detection of pancreatic cancer and its relation to 
life span, and the case and comparison cohorts trended in opposite directions.  This difference in 
trend may be attributed to the impact of the family history of the high-risk patients.  When the 
familial cohort was separated by germline mutations, both groups showed a decrease trend for 
this question, showing there is no difference based on mutation status.  These individuals already 
have a pre-conceived idea of their susceptibility to pancreatic cancer, and no matter how 
beneficial the EUS may be, these individuals may still allow their personal experiences to drive 
their risk perception.  This is common trend noted throughout this study and in past research, 
where patients cannot separate their qualitative cancer risk and their emotionally driven cancer 
risk (Keogh et al., 2011). 
Questions relating to the impact of family history and familial support seemed to show 
the most disparity in the trends between the two groups.  The effects of family history on the 
participant’s risk to develop pancreatic cancer showed trend differences between the case and 
comparison cohorts.  Previous studies (Axilbund et al., 2005) have shown that patients from 
pancreatic cancer kindreds find genetic counseling valuable.  The results of the current study 
seem to suggest that family history is a strong component for a patient’s risk perception, even if 
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it is opposite of what is stated by a medical professional.  This result was seen in previous studies 
as well, where women from unexplained, high-risk breast cancer families could not separate their 
perceived risk from their emotional response to their risk (Keogh et al., 2011).  When evaluating 
surveillance, high-risk kindreds would be more likely to band together and seek out surveillance 
for a disease affecting their relatives.  An individual with no family history would likely not 
receive surveillance and would only have the influence of the family as it relates to having the 
EUS for diagnostic purposes.  The support of an individual’s family also showed a trend for the 
case cohort as it relates to the potential seriousness of pancreatic cancer.  Many of these 
individuals were encouraged by their family to have the procedure.  Perhaps if they did not have 
the support of their family, they would not have sought surveillance.   
Certain aspects of the health intervention portion showed trend differences between the 
two groups.  The case cohort seemed to be driven by the emotional impact of pancreatic cancer, 
regardless of having the EUS.  This emotional impact is quite evident; this population also 
scored high when asked if they wanted to do everything they could to prevent pancreatic cancer.  
It seems that, although this cohort wants to pursue all surveillance available, their perception of 
their future health is more influenced by their family history. They likely have family members 
who had undergone surveillance and still battled pancreatic cancer.  They may also have a family 
history of pancreatic cancer that still remains despite the result of a single EUS procedure being 
normal.  Keogh et al. described this as the fatalism group.  This group viewed their risk as 
inevitable, and was not diligent with surveillance, which is different than this population.  While 
they may have the fatalistic view because of their familial history, they continued to pursue EUS. 
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6.1 LIMITATIONS 
The results presented in this study are preliminary and several limitations are present.  Firstly, 
the sample size is small and does not lend itself to results with statistical significance.  The 
pancreatic cancer patient population is also small, with the hereditary predisposition syndrome 
population being even smaller.  It may take a much longer recruitment period to capture a greater 
number of high-risk individuals.   
Secondly, all participants in this study were Caucasian.  There is a question about 
whether the trends seen in this study would translate to other ethnic, racial, or socioeconomic 
groups.   
Thirdly, these individuals were also those who were actively seeking surveillance and 
genetic counseling.  This was an unavoidable limitation because recruitment was done through 
the PAGER study that required participants to be in a UPMC facility.  This study did not capture 
those individuals who may be at high-risk but who are not actively seeking medical 
interventions. 
Lastly, insurance coverage for a surveillance procedure in the healthy population where 
an established protocol has not been established has been a problem.  Some cost-effectiveness vs. 
benefit studies have been done (Stoita et al., 2011) but more information needs to be collected.  
With an extended recruitment period, there may be individuals who cannot fully participate in 
the study because their insurance will not cover the procedure. 
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6.2 FUTURE STUDIES 
As previously stated, this study is intended to be the stepping stone towards a larger study in the 
hopes that a extended recruitment period could enroll more individuals from both patient 
populations.  A power calculation can be done to determine the number of participants needed to 
achieve statistical significance.  An important feature of this study is those high-risk individuals 
who do not pursue genetic counseling and/or surveillance.  Since one individual expressed his 
frustrations with his family for not pursuing EUS, future studies may focus on the proband’s 
family members who are not seeking surveillance.  If we can identify those people, we may be 
able to compare potential barriers within a family. 
 We also would have liked to assess their personal risk perception on a scale from one to 
ten.  If the patients can quantify their risk, this may give researchers a better understanding of the 
trends being seen in the data.  It is also important to understand their risk perception when there 
are no survivors in the family.  We may be able to evaluate the perceived risk of familial 
pancreatic cancer individuals to other individuals from a hereditary cancer family that tends to 
have more survivors, like HBOC or HNPCC. 
Future studies will also help healthcare providers give more accurate counseling to this 
population.  The hope is that we can better understand the procedure itself as well as the impact 
it has on this population. 
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7.0  CONCLUSIONS 
This study is the first of its kind, and is the stepping-stone in understanding the psychosocial 
impact of surveillance for this disease in this specific population.  Many studies (Keller et al., 
2005; Meiser et al., 2008) have been done looking at the capability and psychosocial impact of 
more regularly used surveillance methods, like mammography and colonoscopy.  The hope is 
that the EUS can be included in the list with those procedures as more research is performed and 
more information is gathered. 
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APPENDIX A 
INSTITUTIONAL REVIEW BOARD LETTER OF APPROVAL 
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University of Pittsburgh  
Institutional Review Board 
 
3500 Fifth Avenue 
Ground Level 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 
(fax) http://www.irb.
pitt.edu 
  
Memorandum 
    
To: Randall Brand, MD 
From: Margaret Hsieh, MD, Vice Chair 
Date: 10/5/2011 
IRB#: MOD07030072-28  / PRO07030072 
Subjec
t: 
The Pancreatic Adenocarcinoma Gene Environment Risk (PAGER) study - A prospective cohort study of 
patients at risk or having pancreatic disease 
 
The University of Pittsburgh Institutional Review Board reviewed and approved the requested 
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.  
Modification Approval Date: 9/27/2011 
Expiration Date: 4/20/2012 
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the modifications can be undertaken by 
investigators until they have received approval from the UPMC Fiscal Review Office. 
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems involving risks to subjects 
or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)].  The IRB Reference Manual (Chapter 3, Section 3.3) describes the 
reporting requirements for unanticipated problems which include, but are not limited to, adverse events.  If you have any 
questions about this process, please contact the Adverse Events Coordinator at 412-383-1480. 
The protocol and consent forms, along with a brief progress report must be resubmitted at least one month prior to the renewal 
date noted above as required by FWA00006790 (University of Pittsburgh), FWA00006735 (University of Pittsburgh Medical 
Center), FWA00000600 (Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
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APPENDIX B 
QUESTIONNAIRES 
B.1 LIKERT QUESTIONNAIRE 
The attached questionnaire is the set of questions all participants answered.  Participants 
answered this questionnaire after genetic counseling/before the EUS and after the EUS. 
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B.2 INITIAL VISIT ADDITIONAL QUESTIONNAIRE 
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B.3 RETURN VISIT ADDITIONAL QUESTIONNAIRE 
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APPENDIX C 
NARRATIVE TRANSCRIPTIONS 
C.1 PRE-TEST RESPONSES 
PA1091: “All other cancers give you a warning.  You might bleed or hurt.  But not pancreatic 
cancer.” 
PA0527: “I strongly believe this procedure can find cancer early and I can live longer because of 
it.” 
PA1729: “Having a background [and] professional experience with EUS helps my 
understanding.  I feel that the possible early pancreatic cancer detection “or risk detection” 
increases/improves my chances of long term survival.” 
PA0215: “I am on a 3 mo. schedule [for] EUS-MRI.  If I understand correctly, the cysts were not 
seen on the EUS.  It showed on the MRI.” 
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C.2 POST-TEST RESPONSES 
PA0557: “As a member of the mental health profession (an LCSW and an RN), I am pleased that 
you are considering the impact that emotional health has on the development of disease.  The 
EUS is one of many screening tests I have since I have a history of personal cancer along with 
numerous first-degree family members with cancer, including pancreatic (brother).  I also have 
Lynch syndrome.  Of my many screenings including CAT, MRI, ultrasounds, etc, the EUS has 
become one of the most important to me for monitoring my diffuse pancreatic cysts.  Even 
though I realize the importance of constant surveillance in this disease, so many continual 
screenings can put much more stress on a patient and create anxiety while awaiting results.  
However, after several years, this has just become part of my life!” 
C.3 PRE- AND POST-TEST RESPONSES 
PA0998: “I am glad that early detection work is being done.  It may help my two nieces who are 
at very high risk, and many others.”   
“Full speed ahead – you are on the right track.” 
PA0486: “Cysts to me aren’t as scary because I have had breast cysts since 30.” 
 “I think that whether I get pancreatic cancer or not, is total out of my control.  I have 
great faith in the workings of science and participate in the EUS to continue the search for more 
information.” 
PA0469: “I have found it impossible to get my first cousins to discuss pancreatic cancer with 
their physicians and family.  My cousins do not want to discuss this subject.” 
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 “I’ve told my family how to find a doctor and what information to gather.  They just 
don’t want to [talk] about it.  I don’t understand it.” 
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APPENDIX D 
FAMILY HISTORY PEDIGREES 
The following is a key for the pedigrees below: 
 
 
PA1652   PA1324       PA0469  PA0998 
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PA1091    PA0557  PA0486  PA0527 
 
 
PA1559       PA1680  PA0296  PA1087 
 
 
PA0892     PA1027         PA1729 
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